Identification

Name
Trifluoperazine
Accession Number
DB00831  (APRD00173, DB08616)
Type
Small Molecule
Groups
Approved, Investigational
Description

A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. [PubChem]

Structure
Thumb
Synonyms
  • 10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine
  • 10-[3-(4-METHYL-piperazin-1-yl)-propyl]-2-trifluoromethyl-10H-phenothiazine
  • Trifluoperazina
  • Trifluoperazine
  • Trifluoperazinum
  • Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine
  • Trifluoroperazine
  • Trifluperazine
External IDs
NSC-17474 / RP-7623
Product Ingredients
IngredientUNIICASInChI Key
Trifluoperazine Hydrochloride6P1Y2SNF5V440-17-5BXDAOUXDMHXPDI-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PMS Trifluoperazine HCl Syrup 11.8mg/mlSyrup10 mgOralPharmascience Inc1988-12-312012-03-14Canada
PMS Trifluoperazine Tab 10mgTablet10 mgOralPharmascience Inc1988-12-312012-03-14Canada
PMS Trifluoperazine Tab 1mgTablet1 mgOralPharmascience Inc1988-12-311996-09-10Canada
PMS Trifluoperazine Tab 20mgTablet20 mgOralPharmascience Inc1988-12-311996-09-10Canada
PMS Trifluoperazine Tab 2mgTablet2 mgOralPharmascience Inc1988-12-312012-03-14Canada
PMS Trifluoperazine Tab 5mgTablet5 mgOralPharmascience Inc1988-12-312012-03-14Canada
Stelazine Tab 10mgTablet10 mgOralSmithkline Beecham Pharma Division Of Smithkline Beecham Inc1993-12-312000-11-30Canada
Stelazine Tab 1mgTablet1 mgOralSmithkline Beecham Pharma Division Of Smithkline Beecham Inc1993-12-312000-11-30Canada
Stelazine Tab 2mgTablet2 mgOralSmithkline Beecham Pharma Division Of Smithkline Beecham Inc1992-12-312000-10-18Canada
Stelazine Tab 5mgTablet5 mgOralSmithkline Beecham Pharma Division Of Smithkline Beecham Inc1993-12-312000-09-28Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Novo-flurazine Tab 1mgTablet1.18 mgOralNovopharm Limited1971-12-311996-09-10Canada
Novo-flurazine Tab 20mgTablet23.6 mgOralNovopharm Limited1971-12-311996-09-10Canada
Novo-trifluzine - Tab 10mgTablet11.8 mgOralNovopharm Limited1971-12-312013-06-03Canada
Novo-trifluzine - Tab 2mgTablet2.36 mgOralNovopharm Limited1971-12-312013-06-03Canada
Novo-trifluzine - Tab 5mgTablet5.9 mgOralNovopharm Limited1971-12-312013-06-03Canada
PMS-trifluoperazine HCl Syr 1.18mg/mlSyrup1 mgOralPharmascience Inc1988-12-312012-10-17Canada
TrifluoperazineTablet, film coated2 mg/1OralStat Rx USA1981-11-202018-02-08Us
Trifluoperazine HydrochlorideTablet, film coated1 mg/1OralUpsher Smith Laboratories2015-03-09Not applicableUs
Trifluoperazine HydrochlorideTablet, film coated10 mg/1OralMylan Pharmaceuticals1997-08-29Not applicableUs00378 2410 01 nlmimage10 fc477e1b
Trifluoperazine HydrochlorideTablet, film coated5 mg/1OralRemedy Repack2012-09-27Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Stelabid ForteTrifluoperazine (2 mg) + Isopropamide (7.5 mg)TabletOralGlaxosmithkline Inc1993-12-312002-07-31Canada
Stelabid No 1Trifluoperazine (1 mg) + Isopropamide (5 mg)TabletOralGlaxosmithkline Inc1993-12-312002-01-29Canada
Stelabid No 2Trifluoperazine (2 mg) + Isopropamide (5 mg)TabletOralGlaxosmithkline Inc1993-12-312002-01-29Canada
International/Other Brands
Eskazine / Eskazinyl / Jatroneural / Modalina / Stelazine / Terfluzine / Trifluoperaz / Triftazin
Categories
UNII
214IZI85K3
CAS number
117-89-5
Weight
Average: 407.496
Monoisotopic: 407.164303088
Chemical Formula
C21H24F3N3S
InChI Key
ZEWQUBUPAILYHI-UHFFFAOYSA-N
InChI
InChI=1S/C21H24F3N3S/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22,23)24/h2-3,5-8,15H,4,9-14H2,1H3
IUPAC Name
10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine
SMILES
CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1

Pharmacology

Indication

For the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation.

Associated Conditions
Pharmacodynamics

Trifluoperazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Trifluoperazine has not been shown effective in the management of behaviorial complications in patients with mental retardation.

Mechanism of action

Trifluoperazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
ANeuron-specific vesicular protein calcyon
antagonist
Human
AAlpha-1A adrenergic receptor
antagonist
Human
UCalmodulin
inhibitor
Human
UTroponin C, slow skeletal and cardiac musclesNot AvailableHuman
UProtein S100-A4
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic.

Route of elimination
Not Available
Half life

10-20 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include agitation, coma, convulsions, difficulty breathing, difficulty swallowing, dry mouth, extreme sleepiness, fever, intestinal blockage, irregular heart rate, low blood pressure, and restlessness.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineTrifluoperazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineTrifluoperazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineTrifluoperazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineTrifluoperazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineTrifluoperazine may decrease the vasoconstricting activities of 4-Methoxyamphetamine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Trifluoperazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Trifluoperazine can be increased when it is combined with Abiraterone.Approved
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Trifluoperazine.Approved, Investigational
AcepromazineTrifluoperazine may increase the antihypertensive activities of Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Adipiplon.Investigational
AdrafinilTrifluoperazine may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Trifluoperazine.Approved
AgmatineTrifluoperazine may decrease the vasoconstricting activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Trifluoperazine.Approved, Illicit
AlfuzosinAlfuzosin may increase the antihypertensive activities of Trifluoperazine.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Allopregnanolone.Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Trifluoperazine.Approved, Investigational
AloglutamolAloglutamol can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Trifluoperazine.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Trifluoperazine.Approved, Withdrawn
AluminiumAluminium can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AmantadineThe therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Amantadine.Approved
AmibegronTrifluoperazine may decrease the vasoconstricting activities of Amibegron.Investigational
AmiodaroneAmiodarone may increase the orthostatic hypotensive activities of Trifluoperazine.Approved, Investigational
AmisulprideTrifluoperazine may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmitrazTrifluoperazine may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineTrifluoperazine may increase the antihypertensive activities of Amitriptyline.Approved
AmlodipineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Trifluoperazine can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineTrifluoperazine may increase the antihypertensive activities of Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Amperozide.Experimental
AmphetamineTrifluoperazine may decrease the stimulatory activities of Amphetamine.Approved, Illicit, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Amrinone.Approved
AnisodamineTrifluoperazine may decrease the vasoconstricting activities of Anisodamine.Investigational
ApomorphineThe therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Apomorphine.Approved, Investigational
ApraclonidineTrifluoperazine may decrease the vasoconstricting activities of Apraclonidine.Approved
AranidipineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Aranidipine.Approved, Investigational
ArbutamineTrifluoperazine may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolTrifluoperazine may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleTrifluoperazine may increase the antihypertensive activities of Aripiprazole.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Trifluoperazine.Investigational
ArtemetherThe serum concentration of Trifluoperazine can be increased when it is combined with Artemether.Approved
ArtemisininThe serum concentration of Trifluoperazine can be increased when it is combined with Artemisinin.Investigational
ArtemotilThe serum concentration of Trifluoperazine can be increased when it is combined with Artemotil.Approved
ArtenimolThe serum concentration of Trifluoperazine can be increased when it is combined with Artenimol.Approved, Investigational
ArtesunateThe serum concentration of Trifluoperazine can be increased when it is combined with Artesunate.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Articaine.Approved
AsenapineTrifluoperazine may increase the antihypertensive activities of Asenapine.Approved
AtenololAtenolol may increase the orthostatic hypotensive activities of Trifluoperazine.Approved
AtovaquoneThe serum concentration of Trifluoperazine can be increased when it is combined with Atovaquone.Approved
AvanafilAvanafil may increase the hypotensive activities of Trifluoperazine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Azaperone.Investigational, Vet Approved
AzelastineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Azimilide.Investigational
AzithromycinThe metabolism of Trifluoperazine can be decreased when combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Baclofen.Approved
BambuterolTrifluoperazine may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BarbitalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Barbital.Illicit
BarnidipineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Trifluoperazine.Experimental
BencyclaneThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Bencyclane.Experimental
BenidipineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Benidipine.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Benzocaine.Approved, Investigational
BenzphetamineTrifluoperazine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Benzyl alcohol.Approved
BepridilThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Trifluoperazine.Approved, Investigational
BevantololTrifluoperazine may increase the antihypertensive activities of Bevantolol.Approved
BezitramideTrifluoperazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
BioallethrinThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Bioallethrin.Approved, Experimental
Bismuth subcitrate potassiumBismuth Subcitrate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Trifluoperazine.Approved
BitolterolTrifluoperazine may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Trifluoperazine.Approved
BortezomibThe metabolism of Trifluoperazine can be decreased when combined with Bortezomib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Trifluoperazine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Trifluoperazine.Approved, Investigational
BrexpiprazoleTrifluoperazine may increase the antihypertensive activities of Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Bromazepam.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Bromisoval.Experimental
BromocriptineThe therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololBucindolol may increase the antihypertensive activities of Trifluoperazine.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Trifluoperazine.Experimental, Investigational
BunazosinBunazosin may increase the antihypertensive activities of Trifluoperazine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Bupivacaine.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Trifluoperazine.Approved
BuprenorphineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Trifluoperazine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Trifluoperazine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Trifluoperazine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Trifluoperazine.Approved
CaffeineThe metabolism of Trifluoperazine can be decreased when combined with Caffeine.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium silicateCalcium silicate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Trifluoperazine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Carbinoxamine.Approved
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Carboxyamidotriazole.Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Carisoprodol.Approved
CaroverineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Caroverine.Experimental
CarteololCarteolol may increase the orthostatic hypotensive activities of Trifluoperazine.Approved
CarvedilolCarvedilol may increase the antihypertensive activities of Trifluoperazine.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Trifluoperazine.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Trifluoperazine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chloroprocaine.Approved
ChloroquineThe serum concentration of Trifluoperazine can be increased when it is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chlorphenamine.Approved
ChlorphentermineTrifluoperazine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproguanilThe serum concentration of Trifluoperazine can be increased when it is combined with Chlorproguanil.Investigational
ChlorpromazineTrifluoperazine may increase the antihypertensive activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chlorzoxazone.Approved
CilnidipineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Cilnidipine.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Cinnarizine.Approved, Investigational
CirazolineTrifluoperazine may decrease the vasoconstricting activities of Cirazoline.Experimental
CitalopramThe metabolism of Trifluoperazine can be decreased when combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clemastine.Approved, Investigational
ClenbuterolTrifluoperazine may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Clevidipine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clopenthixol.Experimental
CloranololCloranolol may increase the orthostatic hypotensive activities of Trifluoperazine.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Trifluoperazine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Trifluoperazine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineTrifluoperazine may increase the antihypertensive activities of Clozapine.Approved
CocaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Trifluoperazine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Trifluoperazine.Approved
CurcuminThe metabolism of Trifluoperazine can be decreased when combined with Curcumin.Approved, Investigational
CyclandelateThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Cyclandelate.Approved
CyclizineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cyclobenzaprine.Approved
Cycloguanil embonateThe serum concentration of Trifluoperazine can be increased when it is combined with Cycloguanil embonate.Experimental
CyclopropaneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cyclopropane.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Trifluoperazine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Trifluoperazine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dantrolene.Approved, Investigational
DapiprazoleDapiprazole may increase the antihypertensive activities of Trifluoperazine.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Trifluoperazine.Investigational
DapsoneThe serum concentration of Trifluoperazine can be increased when it is combined with Dapsone.Approved, Investigational
DarodipineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Darodipine.Experimental
DeferasiroxThe serum concentration of Trifluoperazine can be increased when it is combined with Deferasirox.Approved, Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Desflurane.Approved
DesipramineDesipramine may increase the orthostatic hypotensive activities of Trifluoperazine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineTrifluoperazine may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Trifluoperazine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Trifluoperazine.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Diethyl ether.Experimental
DiethylpropionTrifluoperazine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Trifluoperazine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Diphenhydramine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Diphenoxylate.Approved, Illicit
DipivefrinTrifluoperazine may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Trifluoperazine.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dixyrazine.Experimental
DL-MethylephedrineTrifluoperazine may decrease the vasoconstricting activities of DL-Methylephedrine.Approved
DobutamineTrifluoperazine may decrease the vasoconstricting activities of Dobutamine.Approved
DopexamineTrifluoperazine may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DoramectinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Trifluoperazine can be decreased when combined with Dosulepin.Approved
DotarizineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Trifluoperazine.Approved
DoxepinTrifluoperazine may increase the antihypertensive activities of Doxepin.Approved, Investigational
DoxofyllineTrifluoperazine may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Trifluoperazine.Approved, Investigational
DoxycyclineThe serum concentration of Trifluoperazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved, Illicit
DronedaroneTrifluoperazine may increase the antihypertensive activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Drotebanol.Experimental, Illicit
DroxidopaTrifluoperazine may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Trifluoperazine.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Efonidipine.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Trifluoperazine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Entacapone.Approved, Investigational
EpanololEpanolol may increase the orthostatic hypotensive activities of Trifluoperazine.Experimental
EperisoneThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Eperisone.Approved, Investigational
EphedraTrifluoperazine may decrease the vasoconstricting activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineTrifluoperazine may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineTrifluoperazine may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineTrifluoperazine may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Trifluoperazine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Trifluoperazine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Trifluoperazine.Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Trifluoperazine.Experimental
EscitalopramTrifluoperazine may increase the antihypertensive activities of Escitalopram.Approved, Investigational
EsmololEsmolol may increase the orthostatic hypotensive activities of Trifluoperazine.Approved
EstazolamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Trifluoperazine.Approved, Investigational
EtafedrineTrifluoperazine may decrease the vasoconstricting activities of Etafedrine.Approved
EthanolTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Etifoxine.Investigational, Withdrawn
EtilefrineTrifluoperazine may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Etorphine.Illicit, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Trifluoperazine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Felbamate.Approved
FelodipineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FendilineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Fendiline.Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenoterolTrifluoperazine may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Trifluoperazine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fexofenadine.Approved, Investigational
Fish oilThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Fish oil.Approved, Nutraceutical
FlibanserinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may increase the antihypertensive activities of Trifluoperazine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Trifluoperazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Trifluoperazine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fluticasone propionate.Approved
FluvoxamineThe metabolism of Trifluoperazine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolTrifluoperazine may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fospropofol.Approved, Illicit, Investigational
FostamatinibFostamatinib may increase the hypotensive activities of Trifluoperazine.Approved, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Trifluoperazine.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Gabapentin Enacarbil.Approved, Investigational
GallopamilThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Gallopamil.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GepefrineTrifluoperazine may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Glutethimide.Approved, Illicit
GuanabenzTrifluoperazine may decrease the vasoconstricting activities of Guanabenz.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe serum concentration of Trifluoperazine can be increased when it is combined with Halofantrine.Approved
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Trifluoperazine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Hexobarbital.Approved
HexoprenalineTrifluoperazine may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineTrifluoperazine may decrease the vasoconstricting activities of Higenamine.Investigational
HydrocodoneTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Trifluoperazine.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
HydroxyamphetamineTrifluoperazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxychloroquineThe serum concentration of Trifluoperazine can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved
IloperidoneTrifluoperazine may increase the antihypertensive activities of Iloperidone.Approved
ImipramineTrifluoperazine may increase the antihypertensive activities of Imipramine.Approved
IndacaterolTrifluoperazine may decrease the vasoconstricting activities of Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Indalpine.Investigational, Withdrawn
IndenololIndenolol may increase the orthostatic hypotensive activities of Trifluoperazine.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Indiplon.Investigational
IndoraminIndoramin may increase the antihypertensive activities of Trifluoperazine.Withdrawn
Iofetamine I-123Trifluoperazine may decrease the stimulatory activities of Iofetamine I-123.Approved
IsocarboxazidThe therapeutic efficacy of Trifluoperazine can be increased when used in combination with Isocarboxazid.Approved
IsoetarineTrifluoperazine may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Trifluoperazine.Approved, Vet Approved
IsomethepteneTrifluoperazine may decrease the vasoconstricting activities of Isometheptene.Approved
IsoprenalineTrifluoperazine may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
IsoxsuprineTrifluoperazine may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Isradipine.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ketobemidone.Approved, Investigational
LabetalolLabetalol may increase the antihypertensive activities of Trifluoperazine.Approved
LacidipineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Trifluoperazine.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Trifluoperazine.Approved
LercanidipineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levetiracetam.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Trifluoperazine.Approved, Investigational
LevobunololTrifluoperazine may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levorphanol.Approved
LevosalbutamolTrifluoperazine may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LidocaineThe metabolism of Trifluoperazine can be decreased when combined with Lidocaine.Approved, Vet Approved
LidoflazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Lidoflazine.Experimental
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Trifluoperazine.Approved, Investigational
LisdexamfetamineTrifluoperazine may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
Lithium cationLithium may increase the neurotoxic activities of Trifluoperazine.Experimental
LobeglitazoneThe metabolism of Trifluoperazine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Trifluoperazine can be increased when used in combination with Lofexidine.Approved, Investigational
LoperamideThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Loperamide.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Trifluoperazine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Trifluoperazine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Trifluoperazine.Approved
LumefantrineThe serum concentration of Trifluoperazine can be increased when it is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Lurasidone.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium sulfateThe therapeutic efficacy of Trifluoperazine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ManidipineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Maprotiline.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Medetomidine.Vet Approved
MefloquineThe serum concentration of Trifluoperazine can be increased when it is combined with Mefloquine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Melperone.Approved, Investigational
MentholThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Menthol.Approved
MephedroneTrifluoperazine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineTrifluoperazine may decrease the stimulatory activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Trifluoperazine.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Trifluoperazine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Meptazinol.Experimental
MequitazineTrifluoperazine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Mesoridazine.Approved, Investigational
MetaraminolTrifluoperazine may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Trifluoperazine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineTrifluoperazine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Trifluoperazine.Approved
MethotrimeprazineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxamineTrifluoperazine may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineTrifluoperazine may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methsuximide.Approved
MethyldopaTrifluoperazine may decrease the vasoconstricting activities of Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methylphenobarbital.Approved
MetipranololTrifluoperazine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Trifluoperazine.Approved, Investigational
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Trifluoperazine.Approved, Investigational
MetyrosineTrifluoperazine may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Trifluoperazine can be decreased when combined with Mexiletine.Approved, Investigational
MibefradilThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Mibefradil.Investigational, Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Trifluoperazine.Approved, Illicit
MidodrineTrifluoperazine may decrease the vasoconstricting activities of Midodrine.Approved
MidomafetamineTrifluoperazine may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Trifluoperazine can be decreased when combined with Midostaurin.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved, Investigational
MirabegronTrifluoperazine may decrease the vasoconstricting activities of Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Trifluoperazine.Investigational
MirtazapineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MizoribineThe serum concentration of Trifluoperazine can be increased when it is combined with Mizoribine.Investigational
MMDATrifluoperazine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Trifluoperazine.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Trifluoperazine.Approved, Investigational
MoxonidineTrifluoperazine may decrease the vasoconstricting activities of Moxonidine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Trifluoperazine.Approved
NaftopidilThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Trifluoperazine.Approved
NaphazolineTrifluoperazine may decrease the vasoconstricting activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Trifluoperazine.Approved, Investigational
NebivololNebivolol may increase the orthostatic hypotensive activities of Trifluoperazine.Approved, Investigational
NefazodoneTrifluoperazine may increase the antihypertensive activities of Nefazodone.Approved, Withdrawn
NevirapineThe metabolism of Trifluoperazine can be decreased when combined with Nevirapine.Approved
NicardipineTrifluoperazine may increase the antihypertensive activities of Nicardipine.Approved, Investigational
NicergolineNicergoline may increase the antihypertensive activities of Trifluoperazine.Approved, Investigational
NicomorphineTrifluoperazine may increase the hypotensive activities of Nicomorphine.Experimental
NifedipineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Nifedipine.Approved
NiguldipineTrifluoperazine may increase the antihypertensive activities of Niguldipine.Experimental
NiludipineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Niludipine.Experimental
NilvadipineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Nitrazepam.Approved
NitrendipineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Nitrendipine.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Nitrous oxide.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Nordazepam.Approved
NorepinephrineTrifluoperazine may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrineTrifluoperazine may decrease the vasoconstricting activities of Norfenefrine.Experimental
NorfluraneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Normethadone.Approved, Illicit
NortriptylineTrifluoperazine may increase the antihypertensive activities of Nortriptyline.Approved
NylidrinTrifluoperazine may decrease the vasoconstricting activities of Nylidrin.Approved
OctopamineTrifluoperazine may decrease the vasoconstricting activities of Octopamine.Experimental
OlanzapineTrifluoperazine may increase the antihypertensive activities of Olanzapine.Approved, Investigational
OlodaterolTrifluoperazine may decrease the vasoconstricting activities of Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Opium.Approved, Illicit
OrciprenalineTrifluoperazine may decrease the vasoconstricting activities of Orciprenaline.Approved
OrphenadrineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Trifluoperazine can be decreased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Otilonium.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Oxazepam.Approved
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Trifluoperazine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Trifluoperazine.Approved, Illicit, Investigational
OxyfedrineTrifluoperazine may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineTrifluoperazine may decrease the vasoconstricting activities of Oxymetazoline.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaliperidoneTrifluoperazine may increase the antihypertensive activities of Paliperidone.Approved
ParaldehydeTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Trifluoperazine.Approved
Peginterferon alfa-2bThe serum concentration of Trifluoperazine can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Trifluoperazine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trifluoperazine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Trifluoperazine.Approved, Investigational, Vet Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Trifluoperazine.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved
PerazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Perazine.Approved, Investigational
PergolideTrifluoperazine may decrease the vasoconstricting activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Trifluoperazine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Phenazocine.Experimental
PhendimetrazineTrifluoperazine may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Trifluoperazine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Phenoperidine.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the antihypertensive activities of Trifluoperazine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Phenoxyethanol.Approved
PhentermineTrifluoperazine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolamineTrifluoperazine may increase the antihypertensive activities of Phentolamine.Approved
PhenylephrineTrifluoperazine may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineTrifluoperazine may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pimozide.Approved
PinaveriumThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Trifluoperazine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pipamperone.Approved, Investigational
PiperaquineThe serum concentration of Trifluoperazine can be increased when it is combined with Piperaquine.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pipotiazine.Approved, Investigational
PirbuterolTrifluoperazine may decrease the vasoconstricting activities of Pirbuterol.Approved
PiribedilThe therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Piritramide.Approved, Investigational
PizotifenTrifluoperazine may increase the antihypertensive activities of Pizotifen.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Trifluoperazine.Experimental
PomalidomideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pomalidomide.Approved
PractololPractolol may increase the orthostatic hypotensive activities of Trifluoperazine.Approved
PramipexoleTrifluoperazine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Prazepam.Approved, Illicit
PrazosinPrazosin may increase the antihypertensive activities of Trifluoperazine.Approved
PregabalinThe therapeutic efficacy of Trifluoperazine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrenalterolTrifluoperazine may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Prenylamine.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Prilocaine.Approved
PrimaquineThe serum concentration of Trifluoperazine can be increased when it is combined with Primaquine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Trifluoperazine.Approved, Investigational
ProcaterolTrifluoperazine may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trifluoperazine.Approved, Vet Approved
ProguanilThe serum concentration of Trifluoperazine can be increased when it is combined with Proguanil.Approved
PromazinePromazine may increase the antihypertensive activities of Trifluoperazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Promethazine.Approved, Investigational
PropafenonePropafenone may increase the orthostatic hypotensive activities of Trifluoperazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Proparacaine.Approved, Vet Approved
PropericiazineTrifluoperazine may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazinePropiomazine may increase the antihypertensive activities of Trifluoperazine.Approved
PropiverineTrifluoperazine may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Trifluoperazine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Propoxycaine.Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Trifluoperazine.Approved, Investigational
ProtokylolTrifluoperazine may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Proxibarbal.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Trifluoperazine.Approved
PSD502The risk or severity of adverse effects can be increased when Trifluoperazine is combined with PSD502.Investigational
PseudoephedrineTrifluoperazine may decrease the stimulatory activities of Pseudoephedrine.Approved
PyrimethamineThe serum concentration of Trifluoperazine can be increased when it is combined with Pyrimethamine.Approved, Investigational, Vet Approved
PyronaridineThe serum concentration of Trifluoperazine can be increased when it is combined with Pyronaridine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Quazepam.Approved, Illicit
QuetiapineTrifluoperazine may increase the antihypertensive activities of Quetiapine.Approved
QuinacrineThe serum concentration of Trifluoperazine can be increased when it is combined with Quinacrine.Approved, Investigational
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Trifluoperazine.Approved, Investigational
QuinidineTrifluoperazine may increase the antihypertensive activities of Quinidine.Approved, Investigational
QuinineThe serum concentration of Trifluoperazine can be increased when it is combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Quinisocaine.Experimental
RacepinephrineTrifluoperazine may increase the antihypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Raclopride.Investigational
RactopamineTrifluoperazine may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RadicicolThe serum concentration of Trifluoperazine can be increased when it is combined with Radicicol.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ramelteon.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Trifluoperazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Trifluoperazine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Remoxipride.Approved, Withdrawn
ReproterolTrifluoperazine may decrease the vasoconstricting activities of Reproterol.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Trifluoperazine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Trifluoperazine.Approved, Investigational
RilmenidineTrifluoperazine may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RimiterolTrifluoperazine may decrease the vasoconstricting activities of Rimiterol.Experimental
RisperidoneRisperidone may increase the antihypertensive activities of Trifluoperazine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ritanserin.Investigational
RitobegronTrifluoperazine may decrease the stimulatory activities of Ritobegron.Investigational
RitodrineTrifluoperazine may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Trifluoperazine.Approved
RomifidineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Romifidine.Vet Approved
RopiniroleTrifluoperazine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ropivacaine.Approved
RotigotineTrifluoperazine may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Trifluoperazine can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Trifluoperazine.Approved
SalbutamolTrifluoperazine may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalmeterolTrifluoperazine may decrease the vasoconstricting activities of Salmeterol.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Scopolamine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Trifluoperazine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Trifluoperazine.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Seletracetam.Investigational
SepranoloneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the hypotensive activities of Trifluoperazine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Trifluoperazine.Approved
SimeprevirThe metabolism of Trifluoperazine can be decreased when combined with Simeprevir.Approved
SinefunginThe serum concentration of Trifluoperazine can be increased when it is combined with Sinefungin.Experimental
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved
SolabegronTrifluoperazine may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Trifluoperazine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trifluoperazine.Approved, Investigational
SulfadoxineThe serum concentration of Trifluoperazine can be increased when it is combined with Sulfadoxine.Approved, Investigational
SulfametopyrazineThe serum concentration of Trifluoperazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SulpirideTrifluoperazine may increase the antipsychotic activities of Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Trifluoperazine.Approved, Investigational
SuvorexantTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
SynephrineTrifluoperazine may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Trifluoperazine.Approved, Investigational
TafenoquineThe serum concentration of Trifluoperazine can be increased when it is combined with Tafenoquine.Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Trifluoperazine.Investigational
TamsulosinTamsulosin may increase the antihypertensive activities of Trifluoperazine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tasimelteon.Approved, Investigational
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Trifluoperazine.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Trifluoperazine.Approved, Investigational
Tenofovir disoproxilThe metabolism of Trifluoperazine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerazosinTerazosin may increase the antihypertensive activities of Trifluoperazine.Approved
TerbutalineTerbutaline may increase the orthostatic hypotensive activities of Trifluoperazine.Approved
TeriflunomideThe serum concentration of Trifluoperazine can be decreased when it is combined with Teriflunomide.Approved
TerodilineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Trifluoperazine.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Trifluoperazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tetrodotoxin.Investigational
TetryzolineTrifluoperazine may decrease the vasoconstricting activities of Tetryzoline.Approved
ThalidomideTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineTheophylline may increase the hypotensive activities of Trifluoperazine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Thiopental.Approved, Vet Approved
ThioproperazineTrifluoperazine may increase the antihypertensive activities of Thioproperazine.Approved
ThioridazineThioridazine may increase the antihypertensive activities of Trifluoperazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tiagabine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Trifluoperazine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tilidine.Experimental
TimololTimolol may increase the orthostatic hypotensive activities of Trifluoperazine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tizanidine.Approved, Investigational
TolazolineTolazoline may increase the antihypertensive activities of Trifluoperazine.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Tolfenamic Acid.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Trifluoperazine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Trifluoperazine.Approved, Investigational
TranilastThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Tranilast.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tranylcypromine.Approved, Investigational
TrazodoneTrazodone may increase the antihypertensive activities of Trifluoperazine.Approved, Investigational
TretoquinolTrifluoperazine may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriazolamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Triazolam.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Trichloroethylene.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Triflupromazine.Approved, Vet Approved
TrimazosinTrimazosin may increase the antihypertensive activities of Trifluoperazine.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Trimethadione.Approved
TrimethoprimThe serum concentration of Trifluoperazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrifluoperazine may increase the antihypertensive activities of Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Triprolidine.Approved
TromethamineTromethamine can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TulobuterolTrifluoperazine may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Trifluoperazine.Approved, Investigational
UrapidilUrapidil may increase the antihypertensive activities of Trifluoperazine.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Valproic Acid.Approved, Investigational
VardenafilVardenafil may increase the hypotensive activities of Trifluoperazine.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Trifluoperazine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Veralipride.Experimental
VerapamilTrifluoperazine may increase the antihypertensive activities of Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Vigabatrin.Approved
VilanterolTrifluoperazine may decrease the vasoconstricting activities of Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Vilazodone.Approved
VincristineThe excretion of Vincristine can be decreased when combined with Trifluoperazine.Approved, Investigational
VinpocetineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Vortioxetine.Approved, Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Trifluoperazine is combined with WIN 55212-2.Experimental
XamoterolTrifluoperazine may decrease the vasoconstricting activities of Xamoterol.Experimental
XenonThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Xylazine.Vet Approved
XylometazolineTrifluoperazine may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the antihypertensive activities of Trifluoperazine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Trifluoperazine.Approved, Investigational
ZolpidemTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zotepine.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Trifluoperazine can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolTrifluoperazine may increase the antihypertensive activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0014969
KEGG Compound
C07168
PubChem Compound
5566
PubChem Substance
46507961
ChemSpider
5365
BindingDB
79181
ChEBI
45951
ChEMBL
CHEMBL422
Therapeutic Targets Database
DAP000034
PharmGKB
PA451771
IUPHAR
214
Guide to Pharmacology
GtP Drug Page
HET
TFP
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Trifluoperazine
ATC Codes
N05AB06 — Trifluoperazine
AHFS Codes
  • 28:16.08.24 — Phenothiazines
PDB Entries
1a29 / 1ctr / 1lin / 1wrk / 1wrl / 3ko0 / 4rjd
MSDS
Download (73.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Unknown StatusTreatmentPsychosis Nos/Other1
Not AvailableActive Not RecruitingNot AvailableSchizophrenic Disorders1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
  • Glaxosmithkline
  • Sandoz inc
  • Wockhardt eu operations (swiss) ag
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Ivax pharmaceuticals inc
  • Mylan pharmaceuticals inc
  • Watson laboratories inc
Packagers
  • Apotheca Inc.
  • Comprehensive Consultant Services Inc.
  • Heartland Repack Services LLC
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Nucare Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Remedy Repack
  • Sandhills Packaging Inc.
  • Sandoz
  • Stat Rx Usa
  • UDL Laboratories
Dosage forms
FormRouteStrength
TabletOral1.18 mg
TabletOral23.6 mg
TabletOral11.8 mg
TabletOral2.36 mg
TabletOral5.9 mg
SyrupOral1 mg
TabletOral
SyrupOral10 mg
TabletOral1 mg
TabletOral10 mg
TabletOral2 mg
TabletOral20 mg
TabletOral5 mg
TabletOral1 mg/1
Tablet, film coatedOral1 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral2 mg/1
Tablet, film coatedOral5 mg/1
Prices
Unit descriptionCostUnit
Trifluoperazine HCl 10 mg tablet1.7USD tablet
Trifluoperazine 10 mg tablet1.63USD tablet
Trifluoperazine HCl 5 mg tablet1.09USD tablet
Trifluoperazine 5 mg tablet1.08USD tablet
Trifluoperazine HCl 2 mg tablet0.89USD tablet
Trifluoperazine 2 mg tablet0.86USD tablet
Trifluoperazine HCl 1 mg tablet0.59USD tablet
Trifluoperazine 1 mg tablet0.58USD tablet
Apo-Trifluoperazine 20 mg Tablet0.58USD tablet
Apo-Trifluoperazine 10 mg Tablet0.29USD tablet
Apo-Trifluoperazine 5 mg Tablet0.24USD tablet
Apo-Trifluoperazine 2 mg Tablet0.18USD tablet
Apo-Trifluoperazine 1 mg Tablet0.14USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility12.2 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP5.03HANSCH,C ET AL. (1995)
logS-4.52ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00876 mg/mLALOGPS
logP4.87ALOGPS
logP4.66ChemAxon
logS-4.7ALOGPS
pKa (Strongest Basic)8.39ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area9.72 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity110.98 m3·mol-1ChemAxon
Polarizability41.94 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9946
Blood Brain Barrier+0.9814
Caco-2 permeable+0.6856
P-glycoprotein substrateSubstrate0.8529
P-glycoprotein inhibitor IInhibitor0.9058
P-glycoprotein inhibitor IIInhibitor0.9089
Renal organic cation transporterInhibitor0.6842
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9109
CYP450 3A4 substrateNon-substrate0.594
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9144
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorInhibitor0.8995
CYP450 3A4 inhibitorNon-inhibitor0.5618
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8247
Ames testNon AMES toxic0.8944
CarcinogenicityNon-carcinogens0.9446
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8411 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9327
hERG inhibition (predictor II)Inhibitor0.8556
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (10.1 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-03kc-9730000000-49438d7f5a4236b51602
GC-MS Spectrum - EI-BGC-MSsplash10-08mi-8921200000-2aff2d698385cab14cdb
GC-MS Spectrum - CI-BGC-MSsplash10-0002-9000100000-e2406a8adccd141c03e7
Mass Spectrum (Electron Ionization)MSsplash10-03kc-9740000000-e505b8906d154e2285a4
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4i-0000900000-a01e8dfa304983005945
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4i-0000900000-7b23271ee0eec105a7c5
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-06r6-0900500000-0ea8c080e1d078157f50
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-03dl-1900000000-2608f082c54c542054e0
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0229-8910000000-5b36d7157269ff6ba38c
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-0006-0901000000-06a3d20c96b187c19fad
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0110900000-8af3aa3c7acbf89b8b20

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Phenothiazines
Direct Parent
Phenothiazines
Alternative Parents
Alkyldiarylamines / Diarylthioethers / N-methylpiperazines / Benzenoids / 1,4-thiazines / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organofluorides / Hydrocarbon derivatives
show 1 more
Substituents
Phenothiazine / Alkyldiarylamine / Diarylthioether / Aryl thioether / Tertiary aliphatic/aromatic amine / N-alkylpiperazine / N-methylpiperazine / Para-thiazine / 1,4-diazinane / Piperazine
show 15 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
phenothiazines, organofluorine compound, N-alkylpiperazine, N-methylpiperazine (CHEBI:45951)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706]
  3. Lahti RA, Evans DL, Stratman NC, Figur LM: Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur J Pharmacol. 1993 Jun 4;236(3):483-6. [PubMed:8102973]
  4. Schmidt MH, Lee T: Investigation of striatal dopamine D2 receptor acquisition following prenatal neuroleptic exposure. Psychiatry Res. 1991 Mar;36(3):319-28. [PubMed:1676523]
  5. Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. [PubMed:15695070]
  6. Seeman P, Lee T, Chau-Wong M, Wong K: Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 1976 Jun 24;261(5562):717-9. [PubMed:945467]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Clathrin light chain binding
Specific Function
Interacts with clathrin light chain A and stimulates clathrin self-assembly and clathrin-mediated endocytosis.
Gene Name
CALY
Uniprot ID
Q9NYX4
Uniprot Name
Neuron-specific vesicular protein calcyon
Molecular Weight
23433.49 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Seeman P, Lee T, Chau-Wong M, Wong K: Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 1976 Jun 24;261(5562):717-9. [PubMed:945467]
  3. Madrid PB, Polgar WE, Toll L, Tanga MJ: Synthesis and antitubercular activity of phenothiazines with reduced binding to dopamine and serotonin receptors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3014-7. Epub 2007 Mar 24. [PubMed:17407813]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Fujinaga M, Hoffman BB, Baden JM: Receptor subtype and intracellular signal transduction pathway associated with situs inversus induced by alpha 1 adrenergic stimulation in rat embryos. Dev Biol. 1994 Apr;162(2):558-67. [PubMed:8150214]
  4. Huerta-Bahena J, Villalobos-Molina R, Garcia-Sainz JA: Trifluoperazine and chlorpromazine antagonize alpha 1- but not alpha2- adrenergic effects. Mol Pharmacol. 1983 Jan;23(1):67-70. [PubMed:6135146]
Details
4. Calmodulin
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Titin binding
Specific Function
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number...
Gene Name
CALM1
Uniprot ID
P0DP23
Uniprot Name
Calmodulin
Molecular Weight
16837.47 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
  2. Torres-Piedra M, Figueroa M, Hernandez-Abreu O, Ibarra-Barajas M, Navarrete-Vazquez G, Estrada-Soto S: Vasorelaxant effect of flavonoids through calmodulin inhibition: Ex vivo, in vitro, and in silico approaches. Bioorg Med Chem. 2011 Jan 1;19(1):542-6. doi: 10.1016/j.bmc.2010.10.063. Epub 2010 Nov 4. [PubMed:21129983]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Troponin t binding
Specific Function
Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components: Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site fo...
Gene Name
TNNC1
Uniprot ID
P63316
Uniprot Name
Troponin C, slow skeletal and cardiac muscles
Molecular Weight
18402.36 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
  2. Kleerekoper Q, Liu W, Choi D, Putkey JA: Identification of binding sites for bepridil and trifluoperazine on cardiac troponin C. J Biol Chem. 1998 Apr 3;273(14):8153-60. [PubMed:9525919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Rage receptor binding
Specific Function
Not Available
Gene Name
S100A4
Uniprot ID
P26447
Uniprot Name
Protein S100-A4
Molecular Weight
11728.41 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
  2. Malashkevich VN, Dulyaninova NG, Ramagopal UA, Liriano MA, Varney KM, Knight D, Brenowitz M, Weber DJ, Almo SC, Bresnick AR: Phenothiazines inhibit S100A4 function by inducing protein oligomerization. Proc Natl Acad Sci U S A. 2010 May 11;107(19):8605-10. doi: 10.1073/pnas.0913660107. Epub 2010 Apr 26. [PubMed:20421509]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Conversion inhibitor
General Function
Xanthine oxidase activity
Specific Function
Key enzyme in purine degradation. Catalyzes the oxidation of hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric acid. Contributes to the generation of reactive oxygen species. Ha...
Gene Name
XDH
Uniprot ID
P47989
Uniprot Name
Xanthine dehydrogenase/oxidase
Molecular Weight
146422.99 Da
References
  1. Hirata Y, Ishii K, Taguchi T, Suita S, Takeshige K: Conversion of xanthine dehydrogenase to xanthine oxidase during ischemia of the rat small intestine and the effect of trifluoperazine on the conversion. J Pediatr Surg. 1993 Apr;28(4):597-600. [PubMed:8483075]
  2. Greene EL, Paller MS: Calcium and free radicals in hypoxia/reoxygenation injury of renal epithelial cells. Am J Physiol. 1994 Jan;266(1 Pt 2):F13-20. [PubMed:8304479]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein homodimerization activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A4
Uniprot ID
P22310
Uniprot Name
UDP-glucuronosyltransferase 1-4
Molecular Weight
60024.535 Da
References
  1. Kerdpin O, Mackenzie PI, Bowalgaha K, Finel M, Miners JO: Influence of N-terminal domain histidine and proline residues on the substrate selectivities of human UDP-glucuronosyltransferase 1A1, 1A6, 1A9, 2B7, and 2B10. Drug Metab Dispos. 2009 Sep;37(9):1948-55. doi: 10.1124/dmd.109.028225. Epub 2009 Jun 1. [PubMed:19487247]
  2. Fujiwara R, Nakajima M, Yamanaka H, Katoh M, Yokoi T: Interactions between human UGT1A1, UGT1A4, and UGT1A6 affect their enzymatic activities. Drug Metab Dispos. 2007 Oct;35(10):1781-7. Epub 2007 Jul 9. [PubMed:17620344]
  3. Uchaipichat V, Mackenzie PI, Elliot DJ, Miners JO: Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human udp-glucuronosyltransferases. Drug Metab Dispos. 2006 Mar;34(3):449-56. Epub 2005 Dec 28. [PubMed:16381668]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514]

Drug created on June 13, 2005 07:24 / Updated on July 13, 2018 01:03